Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

Dr. Reddy's generic semaglutide approved in Canada, marking G7-first challenge to Novo Nordisk's Ozempic
Small molecule, diabetes, competitive, revenue impact - Read more

BioDuro, CTI Biotechnology partner to build integrated preclinical drug development platform targeting IND submission
Research collaboration, drug discovery, preclinical development, R&D, manufacturing - Read more

Kahimmune Therapeutics, Gustave Roussy collaborate on mRNA neoantigen therapy KAH-001, backed by €190,000 ($222K) funding
Research collaboration, oncology, mRNA therapy, drug discovery, neoantigen immunotherapy - Read more

Greywolf Therapeutics, Genomics partner to develop first-in-class autoimmune disease treatments targeting ERAP variants
Research collaboration, autoimmune, drug discovery, genetic data analytics, small molecule - Read more

OSR Holdings, BCM Europe sign $815M global license agreement for oral immunotherapy VXM01
Licensing deal, oncology, vaccine, milestone payments, royalties - Read more

🚨 Applications are open for the 2026 Lilly Grand Challenge: Aging Reimagined

🔬 $100K in non-dilutive funding (no strings attached)
🏛️ A 2 day pitch at Lilly HQ in Indianapolis (all expenses paid)
🤝 Direct access to Lilly's scientific and venture teams

This year’s focus: Aging Reimagined — New Health Frontiers (mobility, cognition, immune resilience, regenerative medicine).

If you’re building in this space - or know someone who is - don’t miss this!

📅 Deadline: May 15

👉 Learn More and Apply Here: https://linktr.ee/lillygrandchallenge

Pfizer's Elrexfio (elranatamab) Ph3 data shows progression-free survival benefit in relapsed/refractory multiple myeloma
Antibody, cancer, bispecific antibody, multiple myeloma, BCMA target - Read more

GSK's Shingrix strategy shift targeting comorbid patients drives $1.4B Q1 sales, beating analyst forecasts
Vaccine, infectious disease, revenue impact, competitive - Read more

Teva Pharmaceutical beats Q1 estimates, with Austedo leading 41% growth in branded drug sales
Small molecule, neurological, financial, competitive - Read more

AstraZeneca beats Q1 sales expectations at $15.3B, remains confident in $80B 2030 revenue target
Antibody-drug conjugate, oncology, rare disease, financial, strategic - Read more

Regeneron posts $3.6B Q1 revenue, buoyed by Dupixent and Eylea amid first gene therapy approval
Gene therapy, rare disease, monoclonal antibody, financial, revenue impact - Read more

AbbVie shares, guidance rise as Skyrizi and Rinvoq Q1 sales beat analyst expectations
Small molecule, autoimmune, financial, competitive - Read more

Biogen's Leqembi Q1 sales surge 74% as post-Kisunla treatment switches emerge as new growth opportunity
Monoclonal antibody, Alzheimer's disease, competitive, revenue impact - Read more

Avalyn Pharma raises $300M IPO to develop drugs for hard-to-treat lung diseases
Pulmonary, small molecule, clinical-stage - Read more

EnteroBiotix secures £19M ($25M) to advance microbiome therapy into Phase 2b IBS trial
Microbiome therapeutics, gastrointestinal, clinical-stage, rare disease - Read more

Vivacta Biotechnology closes $50M Series A and A+ financing for in vivo CAR-T therapies
Oncology, autoimmune, cell therapy, in vivo CAR-T, clinical-stage - Read more

AstraZeneca restarts £300M ($404M) UK investment after improved drug pricing terms
Strategic, financial, major transaction, operational - Read more

Teva Pharmaceuticals acquires Emalex Biosciences for $700M to gain near-approval Tourette drug ecopipam
Small molecule, neurological, strategic, major transaction - Read more

Chiesi acquires KalVista Pharmaceuticals for $1.9B, gaining rare disease oral HAE treatment Ekterly
Small molecule, rare disease, strategic, major transaction - Read more

Biogen targets early-stage assets to build next-generation pipeline after Apellis acquisition
RNAi, neurological, strategic, major transaction - Read more

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

GSK drops $100M-backed Mersana STING ADC XMT-2056, ending option deal and removing asset from pipeline
ADC, oncology, strategic, pipeline - Read more

AstraZeneca scraps (atuliflapon) after Ph2 failure in moderate-to-severe uncontrolled asthma, FLAP inhibitor dropped from pipeline
Small molecule, respiratory disease, FLAP inhibitor, asthma, leukotriene pathway - Read more

GE HealthCare cuts profit outlook amid rising costs, restructures units and leadership
Medical imaging, diagnostics, financial, operational, strategic - Read more

FDA halts U.S. enrollment in Newron Pharmaceuticals' phase 3 schizophrenia trial after patient death
Small molecule, neurological, regulatory, operational - Read more

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here